Amisulpride

"目录号: HY-14545

GPCR/G ProteinNeuronal Signaling-

Amisulpride(DAN 2163)是多巴胺拮抗剂,对D2和D3受体的Ki分别为2.8 nM和3.2 nM。

Dopamine Receptor

相关产品

Chlorpromazine hydrochloride-Brexpiprazole-Haloperidol-Cabergoline-Clozapine-Cariprazine hydrochloride-L-DOPA-Perphenazine-Dopamine hydrochloride-Oxidopamine hydrobromide-Sertindole-B-HT 920-Azaperone-Fluphenazine dihydrochloride-Iloperidone-

生物活性

Description

Amisulpride(DAN 2163) is an antipsychotic drug, which is a selective dopamine antagonist (Ki=2.8 nM D2 receptor; Ki=3.2 nM D3 receptor).Target: D2/D3 receptorAmisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. In small doses it is also used to treat depression. Amisulpride functions primarily as a D2 and D3 receptor antagonist. It has high affinity for these receptors with dissociation constants of 2.8 nM and 3.2 nM, respectively [1]. At low doses (< or = 10 mg/kg) amisulpride preferentially blocks presynaptic dopamine autoreceptors that control dopamine synthesis and release in the rat, whereas at higher doses (40-80 mg/kg) postsynaptic dopamine D2 receptor occupancy and antagonism is apparent. In contrast, haloperidol is active in all of these paradigms within the same dose range. Amisulpridepreferentially inhibits in vivo binding of the D2/D3 antagonist [3H]raclopride to the limbic system (ID50 = 17 mg/kg) in comparison to the striatum (ID50 = 44 mg/kg) of the rat, increases striatal and limbic tissue 3,4-dihydroxyphenylacetic acid levels with similar potency and efficacy, and preferentially increases extracellular 3,4-dihydroxyphenylacetic acid levels in the nucleus accumbens when compared to the striatum [1]. Clinical indications: Schizophrenia; Bipolar disorder; Dysthymia; FDA Approved Date:  February 2002Toxicity: Insomnia; Hypersalivation; Hyperprolactinaemia; Nausea; Vomiting [2]

Clinical Trial

NCT02095938

CHA University-Handok Pharmaceuticals Co., Ltd.

Schizophrenia-Schizophreniform Disorder

January 2014

Phase 4

NCT01795183

Sanofi

Schizophrenia

November 2012

Phase 4

NCT01615185

Kaohsiung Kai-Suan Psychiatric Hospital

Schizophrenia

January 2008

Phase 4

NCT01246232

Imperial College London-University of Manchester-University College, London

Schizophrenia

September 2011

Phase 4

NCT01105481

National Health Research Institutes, Taiwan

Treatment-resistant Schizophrenia

May 2006

Phase 4

NCT01448499

Geha Mental Health Center

Schizophrenia-Treatment Resistant Disorders

October 2011

NCT00436371

Sanofi

Schizophrenia

May 2005

Phase 4

NCT00245674

Sanofi

Schizophrenia

June 2005

Phase 4

NCT01609153

Heinrich-Heine University, Duesseldorf

Schizophrenia-Schizoaffective Disorder

June 2012

Phase 4

NCT00331981

Sanofi

Schizophrenia

February 2004

Phase 4

NCT01253421

Mclean Hospital-National Institute of Mental Health (NIMH)

Major Depressive Disorder (MDD)

February 2012

NCT01160991

Central Institute of Mental Health, Mannheim-Sanofi

Schizophrenia-Diabetes-Insulin Resistance

May 2004

NCT00126009

Sanofi

Bipolar Disorder

May 2004

Phase 2

NCT00534573

Beersheva Mental Health Center-Tirat Carmel Mental Health Center

Clozapine-induced Hypersalivation

November 2008

Phase 3

NCT01555814

Birte Glenthoj-Glostrup University Hospital, Copenhagen-Rigshospitalet, Denmark-Institute of Psychiatry, London-UMC Utrecht-Copenhagen Hospital Corporation-University of Copenhagen

Schizophrenia-Schizophreniform Disorder-Schizoaffective Disorder

May 2011

NCT01701258

Mclean Hospital-National Institute of Mental Health (NIMH)-Massachusetts General Hospital

Major Depressive Disorder (MDD)-History of Childhood Sexual Abuse (CSA)

November 2012

NCT02661594

Acacia Pharma Ltd

Healthy

November 2013

Phase 1

NCT00761670

Sanofi

Schizophrenia

September 2008

Phase 4

NCT00956189

National Taiwan University Hospital-Yu-Li Veterans Hospital-Yu-Li Hospital

Metabolic Syndrome X

November 2009

NCT00204061

University of Cologne-German Federal Ministry of Education and Research-German Research Network On Schizophrenia-Sanofi-Synthelabo-Department of Psychiatry University of Bonn-Heinrich-Heine University, Duesseldorf-Ludwig-Maximilians - University of Munich

Schizophrenia-Psychoses

January 2001

Phase 4

NCT00419653

University of Jena-Sanofi

Schizophrenia

January 2003

Phase 4

NCT01972711

Sunovion

Schizophrenia

March 2014

Phase 1

NCT00471588

GlaxoSmithKline

Obsessive-Compulsive Disorder

August 2006

Phase 1

NCT02880995

Seoul National University Hospital

Schizophrenia

September 2016

NCT01446328

Haukeland University Hospital-Helse Vest

Schizophrenia-Psychotic Disorders

October 2011

Phase 4

NCT01154829

University of Copenhagen-Glostrup University Hospital, Copenhagen-Rigshospitalet, Denmark-Institute of Psychiatry, London-UMC Utrecht-Copenhagen Hospital Corporation

Schizophrenia

December 2008

NCT02557984

University of Zurich

Addiction

February 2014

NCT01029769

Technische Universität München

Schizophrenia-Schizoaffective Disorder-Schizophreniform Disorder

December 2009

NCT00628290

University of Cologne

Schizophrenia

October 2002

Phase 2

NCT01185418

Chonbuk National University Hospital

Normal Volunteers

March 2009

NCT00926965

Taipei Veterans General Hospital, Taiwan-National Science Council, Taiwan

Tardive Dyskinesia-Neurocognitive Function

January 2003

Phase 4

NCT01248195

Rene Kahn-King's College London-Technische Universität München-University of Manchester-Ludwig-Maximilians - University of Munich-UMC Utrecht

Schizophrenia-Schizophreniform Disorder-Schizoaffective Disorder

May 2011

Phase 4

NCT02051387

Central Institute of Mental Health, Mannheim-University of Cologne

Schizophrenia

January 2013

Phase 1

NCT01498770

Merck Sharp & Dohme Corp.

Bipolar Disorder

April 1, 2013

NCT02307396

Technische Universität München

Schizophrenia-Schizophrenia and Disorders With Psychotic Features-Schizoaffective Disorders

November 2014

Phase 4

NCT02374567

Hannover Medical School

Dementia-Depression-Schizophrenia-Psychosomatic Disorders-Anxiety Disorders

January 2015

Phase 3

NCT02095938

CHA University-Handok Pharmaceuticals Co., Ltd.

Schizophrenia-Schizophreniform Disorder

January 2014

Phase 4

NCT01795183

Sanofi

Schizophrenia

November 2012

Phase 4

NCT01615185

Kaohsiung Kai-Suan Psychiatric Hospital

Schizophrenia

January 2008

Phase 4

NCT01246232

Imperial College London-University of Manchester-University College, London

Schizophrenia

September 2011

Phase 4

NCT01105481

National Health Research Institutes, Taiwan

Treatment-resistant Schizophrenia

May 2006

Phase 4

NCT01448499

Geha Mental Health Center

Schizophrenia-Treatment Resistant Disorders

October 2011

NCT00436371

Sanofi

Schizophrenia

May 2005

Phase 4

NCT00245674

Sanofi

Schizophrenia

June 2005

Phase 4

NCT01609153

Heinrich-Heine University, Duesseldorf

Schizophrenia-Schizoaffective Disorder

June 2012

Phase 4

NCT00331981

Sanofi

Schizophrenia

February 2004

Phase 4

NCT01253421

Mclean Hospital-National Institute of Mental Health (NIMH)

Major Depressive Disorder (MDD)

February 2012

你可能感兴趣的:(Amisulpride)